• Je něco špatně v tomto záznamu ?

Interleukin-4 induces a CD44 high /CD49b high PC3 subpopulation with tumor-initiating characteristics

HHH. Erb, F. Guggenberger, FR. Santer, Z. Culig,

. 2018 ; 119 (5) : 4103-4112. [pub] 20180119

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001040

Pro- and anti-inflammatory cytokines may influence proliferation, migration, invasion, and other cellular events of prostate cancer (PCa) cells. The hyaluronan receptor CD44, which is regulated by Interleukin (IL)-4, is a prostate basal cell marker. CD44high /CD49bhigh expressing cells have been demonstrated to have tumor-initiating characteristics. Here, we aimed to analyze the effects of long-term IL-4 treatment on CD44/CD49b expression, migration, proliferation, and clonogenic potential of basal-like PCa cells. To this end PC3 cells were treated over 30 passages with 5 ng/mL IL-4 (PC3-IL4) resulting in an increased population of CD44high expressing cells. This was concurrent with a clonal outgrowth of cuboid-shaped cells, with increased size and light absorbance properties. Flow cytometry revealed that the PC3-IL4 CD44high expressing subpopulation corresponds to the CD49bhigh population. Isolation of the PC3-IL4 CD44high /CD49bhigh subpopulation via fluorescence-associated cell sorting showed increased migrative, proliferative, and clonogenic potential compared to the CD44low /CD49blow subpopulation. In conclusion, IL-4 increases a PC3 subpopulation with tumor-initiating characteristics. Thus, IL-4, similar to other cytokines may be a regulator of tumor-initiation and hence, may present a suitable therapy target in combination with current treatment options.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001040
003      
CZ-PrNML
005      
20200121143726.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jcb.26607 $2 doi
035    __
$a (PubMed)29236307
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Erb, Holger H H $u Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany.
245    10
$a Interleukin-4 induces a CD44 high /CD49b high PC3 subpopulation with tumor-initiating characteristics / $c HHH. Erb, F. Guggenberger, FR. Santer, Z. Culig,
520    9_
$a Pro- and anti-inflammatory cytokines may influence proliferation, migration, invasion, and other cellular events of prostate cancer (PCa) cells. The hyaluronan receptor CD44, which is regulated by Interleukin (IL)-4, is a prostate basal cell marker. CD44high /CD49bhigh expressing cells have been demonstrated to have tumor-initiating characteristics. Here, we aimed to analyze the effects of long-term IL-4 treatment on CD44/CD49b expression, migration, proliferation, and clonogenic potential of basal-like PCa cells. To this end PC3 cells were treated over 30 passages with 5 ng/mL IL-4 (PC3-IL4) resulting in an increased population of CD44high expressing cells. This was concurrent with a clonal outgrowth of cuboid-shaped cells, with increased size and light absorbance properties. Flow cytometry revealed that the PC3-IL4 CD44high expressing subpopulation corresponds to the CD49bhigh population. Isolation of the PC3-IL4 CD44high /CD49bhigh subpopulation via fluorescence-associated cell sorting showed increased migrative, proliferative, and clonogenic potential compared to the CD44low /CD49blow subpopulation. In conclusion, IL-4 increases a PC3 subpopulation with tumor-initiating characteristics. Thus, IL-4, similar to other cytokines may be a regulator of tumor-initiation and hence, may present a suitable therapy target in combination with current treatment options.
650    _2
$a nádorová transformace buněk $x metabolismus $x patologie $7 D002471
650    _2
$a lidé $7 D006801
650    _2
$a antigeny CD44 $x biosyntéza $7 D018960
650    _2
$a integrin alfa2 $x biosyntéza $7 D039421
650    _2
$a interleukin-4 $x metabolismus $7 D015847
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a buňky PC-3 $7 D000078722
650    _2
$a nádory prostaty $x metabolismus $x patologie $7 D011471
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Guggenberger, Fabian $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
700    1_
$a Santer, Frédéric R $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
700    1_
$a Culig, Zoran $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Annés University Hospital Brno, Brno, Czech Republic.
773    0_
$w MED00002577 $t Journal of cellular biochemistry $x 1097-4644 $g Roč. 119, č. 5 (2018), s. 4103-4112
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29236307 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20200121144103 $b ABA008
999    __
$a ok $b bmc $g 1363980 $s 1039163
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 119 $c 5 $d 4103-4112 $e 20180119 $i 1097-4644 $m Journal of cellular biochemistry $n J Cell Biochem $x MED00002577
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace